- Home
- NBIX
as 11-15-2024 4:00pm EST
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
| Founded: | 1992 | Country: | United States |
| Employees: | 1448 | City: | SAN DIEGO |
| Market Cap: | 11.8B | IPO Year: | 1996 |
| Target Price: | $163.91 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 24 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.73 | EPS Growth: | 97.40 |
| 52 Week Low/High: | $108.14 - $157.98 | Next Earning Date: | 10-30-2024 |
| Revenue: | $2,242,800,000 | Revenue Growth: | 25.72% |
| Revenue Growth (this year): | 26.97% | Revenue Growth (next year): | 16.69% |
Stock Insider Trading Activity of Neurocrine Biosciences Inc. (NBIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Boyer David W. | NBIX | Chief Corp. Affairs Officer | Oct 3 '24 | Sell | $113.66 | 1,295 | $147,189.70 | 377 | |
| Boyer David W. | NBIX | Chief Corp. Affairs Officer | Sep 13 '24 | Sell | $121.88 | 3,461 | $421,828.06 | 377 |
Latest Neurocrine Biosciences Inc. News
NBIX Breaking Stock News: Dive into NBIX Ticker-Specific Updates for Smart Investing
Argus Research
5 days ago
NBIX: Raising target price to $133.00
Simply Wall St.
5 days ago
High Growth Tech Stocks Featuring Three Prominent US Companies
Simply Wall St.
9 days ago
Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality
PR Newswire
10 days ago
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
Argus Research
12 days ago
NBIX: Raising target price to $128.00
PR Newswire
12 days ago
Neurocrine Biosciences to Participate at Investor Conferences in November
PR Newswire
13 days ago
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
PR Newswire
13 days ago
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
Compare NBIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBIX Neurocrine Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.